Sign In
Buy ILMN
$170.93
+8.38 (+5.16%)
At Close: Jun 03, 2026
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
09:15am, Tuesday, 15'th Apr 2025
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILM
Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025
04:05pm, Thursday, 10'th Apr 2025
SAN DIEGO , April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025.
Illumina price target lowered to $85 from $90 at Citi
06:19am, Monday, 07'th Apr 2025
Citi lowered the firm's price target on Illumina to $85 from $90 and keeps a Neutral rating on the shares as part of a Q1 preview for the life science tools and diagnostics group. The firm believes ta
Here's Why Illumina (ILMN) is a Strong Value Stock
10:46am, Friday, 04'th Apr 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders
07:25am, Saturday, 29'th Mar 2025
Keith Meister, Corvex Management's chief investment officer, will join Illumina's board starting March 28. He's no stranger to the world of biotech.
Is Illumina Undervalued After An 83% Drop In Its Stock Price?
08:35am, Thursday, 27'th Mar 2025
The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
09:00am, Tuesday, 25'th Mar 2025
Stephen MacMillan to retire from the Board SAN DIEGO , March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced cha
Activist investor Keith Meister to join Illumina's board, WSJ reports
08:18am, Tuesday, 25'th Mar 2025
Activist investor Keith Meister will join the board of gene-sequencing maker Illumina , and current board member Scott Gottlieb will become chairman, the Wall Street Journal reported on Tuesday, citin
Activist Investor Meister to Join Illumina's Board
08:00am, Tuesday, 25'th Mar 2025
Keith Meister's hedge fund Corvex Management has a 2.5% stake in the gene-sequencing machine maker.
Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain?
12:51pm, Monday, 24'th Mar 2025
ILMN-NashBio's AGD initiative achieves the milestone of completing 250,000 whole genomes.
Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery
09:15am, Wednesday, 19'th Mar 2025
Creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program AGD members are using the population-level insights
Why Illumina (ILMN) is a Top Value Stock for the Long-Term
10:47am, Tuesday, 18'th Mar 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
JAZZ or ILMN: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 14'th Mar 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value inv
Illumina lowers outlook due to China sales ban, to cut $100 million in costs
04:22pm, Monday, 10'th Mar 2025
Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban on imports of its genetic sequencing instruments.
Illumina addresses recent developments in China
04:10pm, Monday, 10'th Mar 2025
Announces Fiscal Year 2025 Non-GAAP Diluted EPS of Approximately $4.50 SAN DIEGO , March 10, 2025 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the Mar
